Huansha Yu

Shanghai, 200433, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Proteogenomic characterization of pulmonary large-cell neuroendocrine carcinoma identifies molecular features and therapeutic strategy.

Proteogenomic characterization of pulmonary large-cell neuroendocrine carcinoma identifies molecular features and therapeutic strategy.

Journal: Science advances

Published: August 12, 2026

Integrative Analyses Identify a cGAS-STING Pathway-Driven Signature With Context-Dependent Roles in Systemic Lupus Erythematosus.

Integrative Analyses Identify a cGAS-STING Pathway-Driven Signature With Context-Dependent Roles in Systemic Lupus Erythematosus.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: October 29, 2025

Efficiency and safety of sintilimab-based induction therapy in potentially resectable stage III non-small cell lung cancer (LungMate-009): an open-label, phase 2 trial.

Efficiency and safety of sintilimab-based induction therapy in potentially resectable stage III non-small cell lung cancer (LungMate-009): an open-label, phase 2 trial.

Journal: EClinicalMedicine

Published: July 10, 2025

Inducible T Cell Costimulator Ligand and Inducible T Cell Costimulator Stratification Identify Dichotomous Tumor Microenvironment and Guide Chemo-Immunotherapy in Small Cell Lung Cancer.

Inducible T Cell Costimulator Ligand and Inducible T Cell Costimulator Stratification Identify Dichotomous Tumor Microenvironment and Guide Chemo-Immunotherapy in Small Cell Lung Cancer.

Journal: MedComm

Published: June 26, 2025

Multi-omics profiling unveils biological and clinical insights into pulmonary sarcomatoid carcinoma.

Multi-omics profiling unveils biological and clinical insights into pulmonary sarcomatoid carcinoma.

Journal: Cell reports. Medicine

Published: May 23, 2025

Surgery after induced anti-PD-L1 therapy and chemotherapy for stage I‒III small-cell lung cancer: a phase 2 trial (LungMate-005).

Surgery after induced anti-PD-L1 therapy and chemotherapy for stage I‒III small-cell lung cancer: a phase 2 trial (LungMate-005).

Journal: Cell discovery

Published: February 12, 2025

Machine learning algorithms integrating positron emission tomography/computed tomography features to predict pathological complete response after neoadjuvant chemoimmunotherapy in lung cancer.

Machine learning algorithms integrating positron emission tomography/computed tomography features to predict pathological complete response after neoadjuvant chemoimmunotherapy in lung cancer.

Journal: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery

Published: December 20, 2024

Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA-IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial.

Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA-IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial.

Journal: BMC medicine

Published: December 01, 2024

Optimal surgical timing for lung cancer following SARS-CoV-2 infection: a prospective multicenter cohort study.

Optimal surgical timing for lung cancer following SARS-CoV-2 infection: a prospective multicenter cohort study.

Journal: BMC cancer

Published: July 11, 2024

Selective inhibition of TGF-β-induced epithelial-mesenchymal transition overcomes chemotherapy resistance in high-risk lung squamous cell carcinoma.

Selective inhibition of TGF-β-induced epithelial-mesenchymal transition overcomes chemotherapy resistance in high-risk lung squamous cell carcinoma.

Journal: Communications biology

Published: June 01, 2024

MAZ promotes tumor proliferation and immune evasion in lung adenocarcinoma.

MAZ promotes tumor proliferation and immune evasion in lung adenocarcinoma.

Journal: Oncogene

Published: May 21, 2024

Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial.

Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial.

Journal: Nature communications

Published: April 22, 2024

Showing 1-12 of 47

Last Updated: 09/26/2026